Literature DB >> 2354313

Effect of urine pH on the stability of doxorubicin and its recovery from bladder instillations.

K F Ilett1, R T Ong, K T Batty, J D Taylor.   

Abstract

Doxorubicin (1 mg/ml) was shown to be stable when added to urine samples with a mean natural pH of 5.4 and in urine buffered to a mean pH of 4.6. However, at alkaline pH (mean = 8.1) there was a biphasic degradation of doxorubicin (mean t1/2 = 3.24 and 89 h respectively). The data indicate that buffering intravesical doxorubicin to pH 4.6 (acetate buffer) or pre-dosing of patients with ammonium chloride may minimise loss of active drug during the time for which the drug is retained in the bladder. Recovery of doxorubicin following 1 hour's retention in the bladder was similar (77%) for doses of 38/48 or 78 mg. It is suggested that a dose of 50 mg (1 mg/ml) is sufficient to ensure an adequate delivery of active drug to the bladder wall.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2354313     DOI: 10.1111/j.1464-410x.1990.tb14790.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  2 in total

Review 1.  Intravesical treatments of bladder cancer: review.

Authors:  Zancong Shen; Tong Shen; M Guillaume Wientjes; Michael A O'Donnell; Jessie L-S Au
Journal:  Pharm Res       Date:  2008-03-28       Impact factor: 4.200

2.  In vitro and in vivo studies of pirarubicin-loaded SWNT for the treatment of bladder cancer.

Authors:  Gang Chen; Yunfeng He; Xiaohou Wu; Yao Zhang; Chunli Luo; Peng Jing
Journal:  Braz J Med Biol Res       Date:  2012-07-12       Impact factor: 2.590

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.